Inflarx N.V., of Jena, Germany, said it expects to raise gross proceeds of about $51 million through the sale of 1.5 million common shares offered at $34 each. The company intends to use net proceeds of the offering and cash on hand to support a phase IIb trial of its anti-C5a antibody in patients with hidradenitis suppurativa (HS) and a phase II program for the candidate in ANCA-associated vasculitis patients.